CINGULATE INC (CING)

US17248W1053 - Common Stock

0.72  +0.04 (+5.91%)

After market: 0.6902 -0.03 (-4.14%)

CINGULATE INC

NASDAQ:CING (9/28/2023, 7:00:00 PM)

After market: 0.6902 -0.03 (-4.14%)

0.72

+0.04 (+5.91%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-14 2023-08-14/amc
Earnings (Next)N/A N/A
Ins Owners22.55%
Inst Owners3.11%
Market Cap9.96M
Shares13.84M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.22
IPO10-07 2021-10-07
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CING Daily chart

Company Profile

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 15 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improve the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of an active pharmaceutical ingredient combined into one small tablet dosage form. The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

Company Info

CINGULATE INC

1901 W. 47Th Place

Kansas City KANSAS

P: 19139422300.0

Employees: 15

Website: https://www.cingulate.com/

CING News

News Image7 days ago - Cingulate Inc.Cingulate Inc. to Present at the LD Micro Main Event XVI

Presentation on Wednesday, October 4th at 02:30 PM PT...

News Image15 days ago - Cingulate Inc.Cingulate Announces Closing of $4.0 Million Public Offering

KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a...

News Image18 days ago - Cingulate Inc.Cingulate Announces Pricing of $4.0 Million Public Offering

KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) --  Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a...

News Image18 days ago - Cingulate Inc.Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S)...

News Image20 days ago - Cingulate Inc.Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Conversion Follows $1.0 Million Capital Investment in August 2023...

News Image24 days ago - Cingulate Inc.Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Data Accepted as Finalist for First Annual Poster Awards

CING Twits

Here you can normally see the latest stock twits on CING, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example